Biocontrol Technology's hyperthermia treatment for AIDS to undergo 30-patient trial.
This article was originally published in The Gray Sheet
Executive Summary
WHOLE-BODY EXTRACORPOREAL HYPERTHERMIA TREATMENT FOR AIDS patients will be tested in a 30-patient study at St. Elizabeth's Hospital in Lafayette, Indiana under a recently cleared FDA protocol. Sponsored by Biocontrol Technology, Inc.'s subsidiary IDT, located in Pittsburgh, Pennsylvania, the study will assess the effects of heating a patient's blood to 107.6 F using the BioLogic-HT System, which is manufactured by HemoCleanse, also of Lafayette.